These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729 [Abstract] [Full Text] [Related]
3. Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation. Mori T, Kato J, Yamane A, Sakurai M, Kohashi S, Kikuchi T, Ono Y, Okamoto S. Int J Hematol; 2012 May; 95(5):564-9. PubMed ID: 22461034 [Abstract] [Full Text] [Related]
5. Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals. Atiq F, Hameli E, Broers AEC, Doorduijn JK, Van Gelder T, Andrews LM, Koch BCP, Versmissen J, de Winter BCM. Eur J Clin Pharmacol; 2018 Jun; 74(6):767-773. PubMed ID: 29500599 [Abstract] [Full Text] [Related]
8. Evaluation of the Interaction of Intravenous and Oral Voriconazole with Oral Cyclosporine in Iranian HSCT Patients. Masoumi HT, Hadjibabaie M, Vaezi M, Ghavamzadeh A. J Res Pharm Pract; 2017 May; 6(2):77-82. PubMed ID: 28616429 [Abstract] [Full Text] [Related]
10. Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Int J Hematol; 2009 Jul; 90(1):103-107. PubMed ID: 19472033 [Abstract] [Full Text] [Related]
14. Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring. Trifilio SM, Scheetz MH, Pi J, Mehta J. Bone Marrow Transplant; 2010 Aug; 45(8):1352-6. PubMed ID: 19966844 [Abstract] [Full Text] [Related]
15. Optimizing cyclosporine A dose post allogeneic hematopoietic stem cell transplantation in paediatric cancer patients. Elnaggar M, Hafez H, Abdallah A, Hamza M, Khalaf MM, El-Haddad A. J Oncol Pharm Pract; 2024 Sep; 30(6):983-991. PubMed ID: 37528663 [Abstract] [Full Text] [Related]
16. [Drug interaction of voriconazole-cyclosporine in children undergoing hematopoietic stem cell transplantation (2013-2014)]. Valenzuela R, Torres JP, Salas C, Gajardo I, Palma J, Catalán P, Santolaya ME, Morales J. Rev Chilena Infectol; 2017 Feb; 34(1):14-18. PubMed ID: 28394976 [Abstract] [Full Text] [Related]
17. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. Schultz KR, Nevill TJ, Balshaw RF, Toze CL, Corr T, Currie CJ, Strong DK, Keown PA. Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845 [Abstract] [Full Text] [Related]
18. Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation. Nygaard M, Hovgaard D, Schjødt IM, Andersen NS, Vindeløv L, Sengeløv H. J Clin Pharm Ther; 2015 Jun; 40(3):358-61. PubMed ID: 25829023 [Abstract] [Full Text] [Related]